Social Media Ideas for Arzdx

Latest updates for Arzdx

Fresh curated links around ARZDX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

finance.yahoo.com /1 month ago

Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases

Read source

seekingalpha.com /4 weeks ago

ARYZTA AG (ARZTY) Q2 2026 Earnings Call Transcript

Read source

qchron.com /3 weeks ago

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord.

Read source

seekingalpha.com /1 month ago

argenx SE (ARGX) Forte Biosciences, Inc. - M&A Call - Slideshow

Read source

seekingalpha.com /1 month ago

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

Read source

biopharmadive.com /3 weeks ago

Argenx jumps on Phase 3 data for blockbuster Vyvgart

The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.

Read source

finance.yahoo.com /2 weeks ago

argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?

Read source

seekingalpha.com /4 weeks ago

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Read source

seekingalpha.com /1 month ago

argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go

Read source

biopharmadive.com /5 days ago

Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

Read source

biopharmadive.com /1 month ago

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.